头孢唑林联合舒巴坦对90株产酶菌的体外抗菌活性  

In vitro antimicrobial activity of cefazolin combined with sulbactam against 90 clinical isolates producing beta-lactamase

作　　者：王选锭[1] 原双晋[1] 刘富光[1] 卞如濂[1] 

机构地区：[1]浙江医科大学附属第二医院

出　　处：《中国抗生素杂志》1998年第1期27-30,共4页Chinese Journal of Antibiotics

摘　　要：用液体培养基试管二倍稀释法测定头孢唑林联合舒巴坦对常见临床分离产酶菌的最低抑菌浓度（ＭＩＣ），并与头孢唑林进行比较。９０株产酶菌中金葡球菌２０株、表葡球菌４株、大肠埃希氏菌３５株、克雷伯氏菌２５株、其它６株，产酶菌鉴定采用ｎｉｔｒｏｃｅｆｉｎ试棒。结果９０株产酶菌中３４株（３７．８％）对头孢唑林耐药（ＭＩＣ≥３２ｍｇ／Ｌ），而仅有１９株（２１．１％）对头孢唑林／舒巴坦（２１）耐药，两者比较有显著差异（Ｐ＜０．０５）。头孢唑林／舒巴坦（２１）对其中６５．６％菌株显示出协同或累加抗菌作用，与头孢唑林比较，ＭＩＣ降至其１／２～１／２８，其中包括２５株耐头孢唑林菌株。此外，对３５株产酶菌株测试，头孢唑林／舒巴坦（２１）较头孢唑林／舒巴坦（１１）显示出更强的体外抗菌活性。Antimicrobial activity of cefazolin (CEZ) combined with a beta-lactamase inhibitor sulbactam (SBT) against beta-lactamase producing strains of clinical isolates was studied in vitro using liquid dilution method compared with cefazolin alone. 90 isolates mainly with Staphylococcus aureus, Escherichia coli and Klebsiella pneumoniae were identified to produce betalactamase by the chromogenic cephalosporin nitrocefin. Among 90 betalactamase producing strains of clinical isolates 37.8% were resistant to cefazolin alone (MIC≥32mg/L), while only 21.1% isolates were resistant to cefazolin+sulbactam (CEZ/SBT) (2∶1), P<0.05. The combination of cefazolin with sulbactam (2∶1) showed significant synergistic effect against 65.6% of the strains, lowered MIC 2-128 folds compared with that of cefazolin alone, including 73.5% of strains which were resistant to cefazolin. In addition, the ratio of CEZ/SBT of 2∶1 resulted in much better antimicrobial effect than that of 1∶1 (the results of 35 strains).

关 键 词：头孢唑林 舒巴坦 细菌 抗菌活性 产酶菌 

分 类 号：R978.11[医药卫生—药品] R978.19[医药卫生—药学]